Latest news and press releases about Acumen Pharmaceuticals, Inc. (ABOS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
Price
| Price | $2.61 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.39 |
| EV / EBITDA | -2.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -136.27% |
| Return on Invested Capital | -118.57% |
| Return on Assets | -90.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · AGEN · ALEC · FATE · INO · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of ABOS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks